This study sought to investigate the diverse effects of dapagliflozin, an SGLT2 inhibitor, on blood glucose control, complete blood count, kidney function, liver markers, and lipid profile in Saudi male and female T2DM patients, uncovering divergent trends in the effects of treatment between sexes in this population. Here, SLC5A2 is linked to type 2 diabetes mellitus.